We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Ionis Pharmaceuticals Inc | NASDAQ:IONS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.67 | -1.55% | 42.42 | 42.41 | 42.42 | 43.76 | 42.36 | 43.54 | 609,187 | 19:48:20 |
From May 2022 to May 2024
By Colin Kellaher
Ionis Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration granted fast-track designation to olezarsen for the treatment of the genetic disease familial chylomicronemia syndrome.
The Carlsbad, Calif., pharmaceutical company said there are currently no approved therapies in the U.S. for the treatment of the disease, which is characterized by severely high levels of plasma triglycerides and a risk of unpredictable and potentially fatal acute pancreatitis.
The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.
Ionis, which last year completed enrollment in a Phase 3 study of olezarsen in adults with familial chylomicronemia syndrome, said it plans to share data from the study in the second half of 2023.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 31, 2023 07:37 ET (12:37 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Ionis Pharmaceuticals Chart |
1 Month Ionis Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
